Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinoma.
Ten patients with Stage III-IV ovarian adenocarcinoma were treated with the drug combination etoposide (VP-16) plus cisplatin (DDP). All patients were in relapse following prior vigorous, uninterrupted treatment with three or more lines of chemotherapy that included (1) courses of weekly 1-mg/kg single-agent DDP, (2) DDP 50 mg/m2 in various combinations with or without cytoxan, adriamycin and hexamethylmelamine q 4 weeks and (3) high-dose methotrexate-leucovorin plus cyclophosphamide (MECY) q 4 weeks. The median duration of treatment prior to starting VP-16-DDP was 27.5 months (range 6 to 53 months). VP-16-DDP was given as a 2-day regimen repeated every 4 weeks. VP-16, 100-150 mg/m2, was given on days 1 and 2, and 50 mg/m2 of DDP on day 1 only. The finding of 50% partial response and 38% stabilization of measurable tumor was remarkable in patients so extensively pretreated. The responses were not due to increased DDP dosage, but rather to an apparent synergism between VP-16 and DDP.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage*; D003536:Cystadenocarcinoma / Q000188:drug therapy*; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011379:Prognosis
D005047:Etoposide; D011034:Podophyllotoxin; D002945:Cisplatin